Paul Aisen

63.7k total citations · 19 hit papers
202 papers, 28.7k citations indexed

About

Paul Aisen is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Paul Aisen has authored 202 papers receiving a total of 28.7k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Physiology, 90 papers in Psychiatry and Mental health and 51 papers in Pharmacology. Recurrent topics in Paul Aisen's work include Alzheimer's disease research and treatments (147 papers), Dementia and Cognitive Impairment Research (88 papers) and Cholinesterase and Neurodegenerative Diseases (41 papers). Paul Aisen is often cited by papers focused on Alzheimer's disease research and treatments (147 papers), Dementia and Cognitive Impairment Research (88 papers) and Cholinesterase and Neurodegenerative Diseases (41 papers). Paul Aisen collaborates with scholars based in United States, France and United Kingdom. Paul Aisen's co-authors include Clifford R. Jack, John Q. Trojanowski, Ronald C. Petersen, Leslie M. Shaw, Michael W. Weiner, William J. Jagust, David S. Knopman, Bruno Vellas, Takeshi Iwatsubo and Giulio Maria Pasinetti and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and PLoS ONE.

In The Last Decade

Paul Aisen

198 papers receiving 28.1k citations

Hit Papers

Hypothetical model of dyn... 2009 2026 2014 2020 2009 2013 2022 2009 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
    2009 3.4k citations Clifford R. Jack, David S. Knopman et al. The Lancet Neurology profile →
  2. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
    2013 3.1k citations Clifford R. Jack, David S. Knopman et al. The Lancet Neurology profile →
  3. Lecanemab in Early Alzheimer’s Disease
    2022 2.7k citations Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine profile →
  4. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    2009 1.6k citations Leslie M. Shaw, Paul Aisen et al. profile →
  5. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
    2014 1.2k citations Rachelle S. Doody, Martin R. Farlow et al. New England Journal of Medicine profile →
  6. The Amyloid-β Pathway in Alzheimer’s Disease
    2021 1.1k citations Harald Hampel, John Hardy et al. Molecular Psychiatry profile →
  7. A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
    2013 903 citations Rachelle S. Doody, Rema Raman et al. New England Journal of Medicine profile →
  8. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
    2013 698 citations Michael W. Weiner, Dallas P. Veitch et al. Alzheimer s & Dementia profile →
  9. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
    2018 471 citations Paul Aisen, Jeffrey L. Cummings et al. New England Journal of Medicine profile →
  10. Testing the Right Target and Right Drug at the Right Stage
    2011 411 citations Reisa A. Sperling, Clifford R. Jack et al. profile →
  11. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
    2019 380 citations Paul Aisen, Jeffrey L. Cummings et al. New England Journal of Medicine profile →
  12. On the path to 2025: understanding the Alzheimer’s disease continuum
    2017 369 citations Paul Aisen, Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
  13. Drug development in Alzheimer’s disease: the path to 2025
    2016 346 citations Jeffrey L. Cummings, Paul Aisen et al. Alzheimer s Research & Therapy profile →
  14. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
    2018 324 citations Dallas P. Veitch, Michael W. Weiner et al. Alzheimer s & Dementia profile →
  15. Aducanumab: Appropriate Use Recommendations
    2021 207 citations Paul Aisen, Stephen Salloway et al. The Journal of Prevention of Alzheimer s Disease profile →
  16. Trial of Solanezumab in Preclinical Alzheimer’s Disease
    2023 186 citations Reisa A. Sperling, Michael Donohue et al. New England Journal of Medicine profile →
  17. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
    2021 155 citations Jeffrey L. Cummings, Paul Aisen et al. Alzheimer s Research & Therapy profile →
  18. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
    2022 130 citations Michael S. Rafii, Reisa A. Sperling et al. Alzheimer s & Dementia profile →
  19. Aducanumab: Appropriate Use Recommendations Update
    2022 126 citations Jeffrey L. Cummings, Paul Aisen et al. The Journal of Prevention of Alzheimer s Disease profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Aisen United States 69 17.4k 10.5k 6.1k 5.3k 4.7k 202 28.7k
Harald Hampel Germany 98 17.8k 1.0× 13.9k 1.3× 7.6k 1.3× 6.0k 1.1× 3.2k 0.7× 496 35.3k
Ralph N. Martins Australia 88 15.6k 0.9× 8.6k 0.8× 7.1k 1.2× 4.0k 0.7× 2.3k 0.5× 591 29.3k
Ann M. Saunders United States 61 19.6k 1.1× 7.9k 0.8× 11.4k 1.9× 4.0k 0.7× 3.3k 0.7× 177 31.5k
Serge Gauthier Canada 85 12.0k 0.7× 15.6k 1.5× 5.2k 0.9× 5.3k 1.0× 4.6k 1.0× 574 35.8k
Anne M. Fagan United States 86 15.2k 0.9× 9.5k 0.9× 6.1k 1.0× 4.9k 0.9× 1.7k 0.4× 290 26.3k
Martin R. Farlow United States 79 12.5k 0.7× 6.3k 0.6× 8.0k 1.3× 5.4k 1.0× 6.9k 1.5× 375 26.9k
Howard Feldman Canada 57 12.4k 0.7× 13.9k 1.3× 5.2k 0.9× 5.2k 1.0× 2.8k 0.6× 242 30.8k
Agneta Nordberg Sweden 83 10.8k 0.6× 5.8k 0.6× 10.2k 1.7× 3.3k 0.6× 6.0k 1.3× 503 25.9k
Hilkka Soininen Finland 105 16.8k 1.0× 16.1k 1.5× 6.5k 1.1× 6.2k 1.2× 2.7k 0.6× 680 40.6k
Randall J. Bateman United States 57 12.0k 0.7× 5.6k 0.5× 4.9k 0.8× 3.6k 0.7× 2.4k 0.5× 249 19.5k

Countries citing papers authored by Paul Aisen

Since Specialization
Citations

This map shows the geographic impact of Paul Aisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Aisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Aisen more than expected).

Fields of papers citing papers by Paul Aisen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Aisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Aisen. The network helps show where Paul Aisen may publish in the future.

Co-authorship network of co-authors of Paul Aisen

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Aisen. A scholar is included among the top collaborators of Paul Aisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Aisen. Paul Aisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jimenez‐Maggiora, Gustavo, Michael Donohue, Michael S. Rafii, Rema Raman, & Paul Aisen. (2025). Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials. The Journal of Prevention of Alzheimer s Disease. 12(1). 100002–100002. 1 indexed citations
2.
Devanarayan, Viswanath, Michael Donohue, Reisa A. Sperling, et al.. (2025). Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. Alzheimer s & Dementia. 21(9). e70702–e70702. 2 indexed citations
3.
Ritchie, Marina, Oliver Langford, Michael Donohue, et al.. (2025). Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites. Alzheimer s Research & Therapy. 17(1). 222–222.
4.
Aisen, Paul, Randall J. Bateman, Damian C. Crowther, et al.. (2024). The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence. Alzheimer s & Dementia. 21(1). e14342–e14342. 9 indexed citations
5.
Mackin, R. Scott, Michelle T. Kassel, Maria Kryza‐Lacombe, et al.. (2024). Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies. Molecular Psychiatry. 30(4). 1267–1276. 1 indexed citations
6.
Winston, Charisse N., Oliver Langford, Rema Raman, et al.. (2023). Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer s Disease. 92(1). 95–107. 10 indexed citations
7.
Sperling, Reisa A., Michael Donohue, Rema Raman, et al.. (2023). Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal of Medicine. 389(12). 1096–1107. 186 indexed citations breakdown →
8.
Dyck, Christopher H. van, Chad J. Swanson, Paul Aisen, et al.. (2022). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 388(1). 9–21. 2741 indexed citations breakdown →
9.
Hampel, Harald, John Hardy, Kaj Blennow, et al.. (2021). The Amyloid-beta Pathway in Alzheimer's Disease. Molecular Psychiatry. 2 indexed citations
10.
Viglietta, Vissia, John O’Gorman, Leslie Williams, et al.. (2016). Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. 86(16_supplement). 9 indexed citations
11.
Risacher, Shannon L., Brenna C. McDonald, Eileen F. Tallman, et al.. (2016). Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. eScholarship (California Digital Library). 49 indexed citations
12.
Doody, Rachelle S., Martin R. Farlow, & Paul Aisen. (2014). Dr. Doody and colleagues reply. New England Journal of Medicine. 370(15). 38 indexed citations
13.
Jack, Clifford R., David S. Knopman, William J. Jagust, et al.. (2013). Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 12(2). 207–216. 3084 indexed citations breakdown →
14.
Weiner, Michael W., Dallas P. Veitch, Paul Aisen, et al.. (2011). The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer s & Dementia. 8(1S). S1–68. 367 indexed citations
15.
Hu, Xiaolan, Eve H. Pickering, Sara Hall, et al.. (2011). Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Translational Psychiatry. 1(11). e54–e54. 30 indexed citations
16.
Hirata‐Fukae, Chiho, Huifang Li, Li Ma, et al.. (2008). Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neuroscience Letters. 450(1). 51–55. 11 indexed citations
17.
Takata, Kazuyuki, Chiho Hirata‐Fukae, Audrey Gray, et al.. (2007). Deglycosylated anti‐amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. European Journal of Neuroscience. 26(9). 2458–2468. 24 indexed citations
18.
Aisen, Paul, Daniel Saumier, Richard Briand, et al.. (2006). A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology. 67(10). 1757–1763. 155 indexed citations
19.
Nishitomi, Kouhei, Gaku Sakaguchi, Yuko Horikoshi, et al.. (2006). BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice2. Journal of Neurochemistry. 99(6). 1555–1563. 84 indexed citations
20.
Ho, Lap, Hiroshi Osaka, Paul Aisen, & Giulio Maria Pasinetti. (1998). Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. Journal of Neuroimmunology. 89(1-2). 142–149. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harald Hampel Breakdown of academic impact, for papers by Ralph N. Martins Breakdown of academic impact, for papers by Ann M. Saunders Breakdown of academic impact, for papers by Serge Gauthier Breakdown of academic impact, for papers by Anne M. Fagan Breakdown of academic impact, for papers by Martin R. Farlow Breakdown of academic impact, for papers by Howard Feldman Breakdown of academic impact, for papers by Agneta Nordberg Breakdown of academic impact, for papers by Hilkka Soininen Breakdown of academic impact, for papers by Randall J. Bateman
Rankless by CCL
2026